TXMD250117C5000
- 0.36
- 0.000.00%
TherapeuticsMD Newsroom
US Manufacturing Index Rises To 43, Highest Since 2020
TherapeuticsMD Third Quarter 2024 Earnings: US$0.049 Loss per Share (Vs US$0.13 Loss in 3Q 2023)
Therapeutics MD GAAP EPS of -$0.05
TherapeuticsMD Shifts Focus With Lower Q3 Losses
TherapeuticsMD | 10-Q: Q3 2024 Earnings Report
TherapeuticsMD | 8-K: TherapeuticsMD Announces Third Quarter 2024 Financial Results
Press Release: TherapeuticsMD Announces Third Quarter 2024 Financial Results
TherapeuticsMD And 2 Other Stocks Under $2 Executives Are Buying
Express News | Corrected-TherapeuticsMD Inc: Qtrly Shr (Not 'eps') Loss From Cont Ops $0.09
TherapeuticsMD | 10-Q: Q2 2024 Earnings Report
Express News | TherapeuticsMD Inc: Qtrly EPS Loss From Cont Ops $0.09
Express News | TherapeuticsMD Inc: Continues to Evaluate a Variety of Strategic Alternatives
TherapeuticsMD | 8-K: TherapeuticsMD Announces Second Quarter 2024 Financial Results
TherapeuticsMD 2Q License Rev $234,000
TherapeuticsMD 2Q Loss Cont Ops 9c/Shr
Express News | TherapeuticsMD Q2 Operating Expenses USD 2.7 Million
Express News | TherapeuticsMD Announces Second Quarter 2024 Financial Results
U.S. Menopause Market Trends Analysis Report 2024-2030 Featuring Pfizer, Novo Nordisk, TherapeuticsMD, Bayer, AbbVie, Pure Encapsulations, and PADAGIS
Nektar, Verastem Among Healthcare Additions in Russell Microcap; Assertio, Sangamo Removed
TherapeuticsMD (TXMD.US): The 2024 Q1 financial report achieved revenue of US$313,000, previous value of US$416,000; earnings per share were -0.07 USD, prior value of -0.24 USD.
TherapeuticsMD (TXMD.US): The 2024 Q1 financial report achieved revenue of US$313,000, previous value of US$416,000; earnings per share were -0.07 USD, prior value of -0.24 USD.